ArriVent BioPharma (AVBP) Change in Accured Expenses (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Change in Accured Expenses data on file, last reported at -$3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 21.54% year-over-year to -$3.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 213.61% YoY), and the FY2025 full-year result was $6.7 million, up 4.55% from the prior year.
• Change in Accured Expenses retreated to -$3.8 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.0 million in Q2 2025 to a low of -$4.9 million in Q1 2025.
• A 4-year average of $828615.4 and a median of $1.6 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 282.23% in 2024 and plunged 406.65% in 2025, its largest moves.
• Tracing AVBP's Change in Accured Expenses over 4 years: stood at $1.6 million in 2023, then jumped by 81.71% to $3.0 million in 2024, then jumped by 49.04% to $4.4 million in 2025, then slumped by 186.45% to -$3.8 million in 2026.
• Business Quant data shows AVBP's Change in Accured Expenses at -$3.8 million in Q1 2026, $4.4 million in Q4 2025, and $91000.0 in Q3 2025.